



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/680,998
Filing Date	October 8, 2003
First Named Inventor	Beyaert et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2676-4554.1US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
AR ↓		US-4,186,183	01-29-1980	Steck et al.	
		US- 4,217,344	08-12-1980	Venierberghe et al.	
		US- 4,235,871	11-25-1980	Papahadjopoulos et al.	
		US- 4,281,975	04-14-1981	Fullerton et al.	
		US- 4,485,054	11-27-1984	Mezei et al.	
		US- 4,501,728	02-26-1985	Geho et al.	
		US- 4,774,085	09-27-1988	Fidler	
		US- 4,797,368	01-10-1989	Carter et al.	
		US- 4,837,028	06-06-1989	Allen	
		US- 4,897,355	01-30-1990	Eppstein et al.	
		US- 4,948,787	08-07-1990	Eppstein et al.	
		US- 5,049,386	09-17-1991	Eppstein et al.	
		US- 5,173,414	12-22-1992	Lebkowski et al.	
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
AR		WO 91/16024	10-31-1991	Vical, Inc.		
AR		WO 91/17424	11-14-1991	Vical, Inc.		
AR		WO 93/24641	12-09-1993	The United States of America		
AR		WO 99/57133	11-11-1999	Vlaams Interuniversitair Instituut Voor Biotechnologie VZW		

Examiner  
Signature

/Agnes Rooke/

Date  
Considered

05/25/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not yet assigned
				Filing Date	October 8, 2003
				First Named Inventor	Beyaert et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	2676-4554.1US
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature	/Agnes Rooke/	Date Considered	05/25/2006
-----------------------	---------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not yet assigned
		Filing Date	October 8, 2003
		First Named Inventor	Beyaert et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 2 of 3	Attorney Docket Number	2676-4554 IUS	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AR		DE VALCK et al., "A20, an inhibitor of cell death, self-associates by its zinc finger domain," 384 FEBS Letters 61-64 (1996). #	
		FUKUSHI, M., "Homosapiens mRNA for HIV-1, Nef-associated factor 1 beta (Naf1 betas); EMHUM DATABASE ENTRY HSA011896, ACCESSION NUMBER AJ011896, October 14, 1998, XP002124741. #	
		FUKUSHI, M., et al., "NAF1 alpha protein (KIAA0113 protein)," TREMBL DATABASE ENTRY A15025, ACCESSION NUMBER Q15025, November 1, 1996, XP02124740. #	
		HENDRICK, B.D., et al., "An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation," EMHUM DATABASE ENTRY HS4131510; ACCESSION NUMBER U41315, May 19, 1996, XP002125387. #	
		HEYNINCK et al., "The Zinc Finger Protein A20 Inhibits TNF-induced NF-kB-dependent Gene Expression by interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kB-inhibiting Protein ABIN," 145 THE JOURNAL OF CELL BIOLOGY 1471-1482 (1999). #	
		MIYAJIMA, N., et al., "Human mRNA for KIAA 0133 gene, partial coding sequence," EMHUM DATABASE ENTRY HSORFA2, ACCESSION NUMBER D30755, May 21, 1994, XP002124739. #	
		NOMURA et al., "mRNA for ORF, partial CDS (fragment)," TRHUM DATABASE ENTRY Q15025; November 1, 1996, ACCESSION NUMBER Q15025, XP002080989. #	
		SONG et al., "The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation," 93 PROC. NATL. ACAD. SCI. USA 6721-6725 (1996). #	
		YEN, R.W.C., et al., "DNA-methyltransferase," SWISSPROT DATABASE ENTRY MTDM_HUMAN; May 1, 1992, ACCESSION NUMBER P26358, XP002080990. #	
		PCT International Search Report, PCT/BE99/00055, dated December 31, 1999 (9 pages). #	
		PCT International Preliminary Examination Report, PCT/BE99/00055, dated August 10, 2000. #	

Examiner Signature	/Agnes Rooke/	Date Considered	05/25/2006
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	Not yet assigned
Filing Date	October 8, 2003
First Named Inventor	Beyaert et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	2676-4554 JUS

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AR		YAMAMOTO et al., "Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer," 107(2) J. CLIN. INVEST. 135-142 (January 2001). #	
		GHOSH, et al., "Missing Pieces in the NF-kappaB Puzzle," 109 CELL S81-S96 (April 2002). #	
		BALDWIN, A.S., "The transcription factor NF-kappaB and human disease," 107(1) J. CLIN. INVEST. 3-6 (January 2001). #	
		NGO et al., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure, Merz et al. ed., pages 14-16 (1994). #	
		ZHANG, et al., "Environment-dependent residue contact energies for proteins," 97(6) PROC. NATL. SCI. 2550-2555 (March 2000). #	
		FUKUSHI et al., (November 1, 1996) Acc. No. Q15025, SPTREMBL_17 database, GenCore Version 4.5, Accessed May 8, 2002. #	
		GUPTA, et al. (March 1, 2001) Acc. No. Q9H1J3, SPTREMBL_17, GenCore Version 4.5, Accessed May 8, 2002. #	
		HEYINCK, K., et al., "Structure-function analysis of the A20-binding inhibitor of NF- $\kappa$ B activation, ABIN-1," 536 FEBS LETTERS 135-140 (2003).	

Examiner  
Signature

/Agnes Rooke/

Date

Considered

05/25/2006

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/702,953

Filed: October 31, 2000

For: NOVEL INHIBITORS OF NF- $\kappa$ B ACTIVATION, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.